Healthcare company Ro has announced a collaboration with Eli Lilly and Company to provide patients with streamlined access to Zepbound (tirzepatide) single-dose vials through LillyDirect’s self-pay pharmacy channel. The integration will allow clinically eligible Ro patients to receive the FDA-approved obesity treatment directly through Ro’s platform. Eli Lilly launched LillyDirect earlier this year, marking the first time a major pharmaceutical company has created its own end-to-end digital healthcare platform.
“Offering Zepbound single-dose vials — the most affordable branded incretin medicine by list price — through another platform to LillyDirect will help ensure broader availability of rigorously tested, FDA-approved and regulated obesity treatment,” said Patrik Jonsson, executive vice president, and president of Lilly Cardiometabolic Health and Lilly USA. “Our goal is to break down barriers and provide patients with safe and effective options they can rely on.”
“Lilly’s release of Zepbound single-dose vials at a lower, self-pay-only price was groundbreaking and reflects the patient-centric model upon which Ro was founded. This integration further streamlines access to the only approved dual GIP and GLP-1 receptor agonist without patients ever having to leave the Ro app, let alone leave their home,” said Zach Reitano, co-founder & CEO of Ro.
Since 2017, Ro has supported millions of patients, including hundreds of thousands beginning weight management journeys. The platform offers comprehensive obesity care including physician access, 24/7 messaging, one-on-one coaching, educational resources, and ongoing monitoring.
